HC Wainwright reissued their buy rating on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in a research report report published on Wednesday, November 8th. The firm currently has a $21.00 target price on the specialty pharmaceutical company’s stock.
A number of other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Tuesday, July 11th. BidaskClub lowered shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Friday, August 4th. Jefferies Group LLC reaffirmed a buy rating and set a $15.00 price objective on shares of Collegium Pharmaceutical in a research report on Thursday, September 21st. Needham & Company LLC reaffirmed a buy rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, Piper Jaffray Companies set a $14.00 price target on shares of Collegium Pharmaceutical and gave the company a buy rating in a research report on Tuesday, July 25th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $19.33.
Collegium Pharmaceutical (NASDAQ COLL) traded up $0.46 during trading hours on Wednesday, hitting $17.60. 681,300 shares of the stock traded hands, compared to its average volume of 474,612. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $17.96.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 110.99% and a negative return on equity of 55.48%. The company had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. During the same quarter last year, the firm posted ($1.13) EPS. The business’s revenue for the quarter was up 2814.6% on a year-over-year basis. sell-side analysts expect that Collegium Pharmaceutical will post -2.63 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/collegium-pharmaceuticals-coll-buy-rating-reaffirmed-at-hc-wainwright/1768044.html.
In other Collegium Pharmaceutical news, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the sale, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 25.76% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. American International Group Inc. boosted its position in Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after acquiring an additional 2,163 shares during the last quarter. Nationwide Fund Advisors boosted its position in Collegium Pharmaceutical by 16.4% during the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 1,422 shares during the last quarter. Voya Investment Management LLC acquired a new position in Collegium Pharmaceutical during the 2nd quarter worth approximately $125,000. Credit Suisse AG boosted its position in Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after acquiring an additional 1,173 shares during the last quarter. Finally, UBS Group AG boosted its position in Collegium Pharmaceutical by 283.2% during the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 10,174 shares during the last quarter. Institutional investors own 77.23% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with our FREE daily email newsletter.